{
    "id": "dbpedia_8098_1",
    "rank": 20,
    "data": {
        "url": "https://finance.yahoo.com/quote/S2P.F/",
        "read_more_link": "",
        "language": "en",
        "title": "Simcere Pharmaceutical Group Limited (S2P.F) Stock Price, News, Quote & History",
        "top_image": "https://pinhole.finance.yahoo.com/chart/S2P.F/__screenshot",
        "meta_img": "https://pinhole.finance.yahoo.com/chart/S2P.F/__screenshot",
        "images": [],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            "S2P.F",
            "Simcere Pharmaceutical Group Limited",
            "S2P.F stock chart",
            "Simcere Pharmaceutical Group Limited stock chart",
            "stock chart",
            "stocks",
            "quotes",
            "finance"
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "Find the latest Simcere Pharmaceutical Group Limited (S2P.F) stock quote, history, news and other vital information to help you with your stock trading and investing.",
        "meta_lang": "en",
        "meta_favicon": "https://s.yimg.com/cv/apiv2/finance/favicon_y19_16x16_custom.png",
        "meta_site_name": "",
        "canonical_link": "https://finance.yahoo.com/quote/S2P.F/",
        "text": "Frankfurt - Delayed Quote • EUR\n\nSimcere Pharmaceutical Group Limited (S2P.F)\n\n0.6300 +0.0250 (+4.13%)\n\nAt close: August 16 at 8:07 AM GMT+2\n\nPrevious Close 0.6050\n\nOpen 0.6300\n\nBid 0.6350 x --\n\nAsk 0.6550 x --\n\nDay's Range 0.6300 - 0.6300\n\n52 Week Range 0.5750 - 0.8950\n\nVolume 952\n\nAvg. Volume 0\n\nMarket Cap (intraday) 1.636B\n\nBeta (5Y Monthly) 0.45\n\nPE Ratio (TTM) 21.00\n\nEPS (TTM) 0.0300\n\nEarnings Date Aug 19, 2024 - Aug 23, 2024\n\nForward Dividend & Yield 0.02 (3.28%)\n\nEx-Dividend Date Jun 18, 2024\n\n1y Target Est --\n\nSimcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. The company focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; COSELA, a trilaciclib hydrochloride for injection; Iremod, an iguratimod tablet; and XIANNUOXIN, a simnotrelvir tablets/ritonavir tablets. The company also offers promotion services for pharmaceutical products. It has a strategic regional licensing partnership with Vivoryon Therapeutics N.V. to develop and commercialize SIM0801 and other drugs in the Greater China region. In addition, the company engages in the manufacture of pharmaceutical ingredients; and property management business. Simcere Pharmaceutical Group Limited was founded in 1995 and is headquartered in Nanjing, China.\n\nwww.simcere.com\n\n7,027\n\nFull Time Employees\n\nDecember 31\n\nFiscal Year Ends\n\nHealthcare\n\nSector\n\nRecent News: S2P.F\n\nView More\n\nAll SEC Filings\n\nCorporate Changes & Voting Matters\n\nPeriodic Financial Reports\n\nProxy Statements\n\nTender Offer/Acquisition Reports\n\nOffering Registrations\n\nPerformance Overview: S2P.F\n\nTrailing total returns as of 8/16/2024, which may include dividends or other distributions. Benchmark is .\n\nYTD Return\n\nS2P.F\n\n10.76%\n\nHANG SENG INDEX\n\n2.25%\n\n1-Year Return\n\nS2P.F\n\n13.74%\n\nHANG SENG INDEX\n\n6.19%\n\n3-Year Return\n\nS2P.F\n\n33.11%\n\nHANG SENG INDEX\n\n33.96%\n\n5-Year Return\n\nS2P.F\n\n45.27%\n\nHANG SENG INDEX\n\n29.46%\n\nCompare To: S2P.F\n\nSelect to analyze similar companies using key performance metrics; select up to 4 stocks.\n\n0.6300\n\n+4.13%\n\nMkt Cap EUR 1.636B\n\nIndustry Drug Manufacturers—Specialty & Generic\n\n3,520.00\n\n+0.57%\n\nMkt Cap JPY 155.603B\n\nIndustry Drug Manufacturers—Specialty & Generic\n\nStatistics: S2P.F\n\nView More\n\nValuation Measures\n\nMarket Cap\n\n1.64B\n\nEnterprise Value\n\n1.56B\n\nTrailing P/E\n\n18.37\n\nForward P/E\n\n--\n\nPEG Ratio (5yr expected)\n\n--\n\nPrice/Sales (ttm)\n\n1.96\n\nPrice/Book (mrq)\n\n1.73\n\nEnterprise Value/Revenue\n\n1.86\n\nEnterprise Value/EBITDA\n\n11.34\n\nFinancial Highlights\n\nProfitability and Income Statement\n\nProfit Margin\n\n10.82%\n\nReturn on Assets (ttm)\n\n4.11%\n\nReturn on Equity (ttm)\n\n9.94%\n\nRevenue (ttm)\n\n6.61B\n\nNet Income Avi to Common (ttm)\n\n714.76M\n\nDiluted EPS (ttm)\n\n0.0300\n\nBalance Sheet and Cash Flow\n\nTotal Cash (mrq)\n\n2.02B\n\nTotal Debt/Equity (mrq)\n\n19.79%\n\nLevered Free Cash Flow (ttm)\n\n-1.05B\n\nResearch Analysis: S2P.F\n\nView More\n\nPeople Also Watch\n\n83B.F 3SBio Inc.\n\n0.7000\n\n+0.72%\n\nSMZ1.F Sino Biopharmaceutical Limited\n\n0.3826\n\n+4.02%\n\nUNC0.F UCB SA\n\n76.00\n\n+2.01%\n\n4RY.F Akeso, Inc.\n\n5.20\n\n+0.97%\n\n1AE.F argenx SE\n\n476.20\n\n+0.27%\n\n49BA.F BeiGene, Ltd.\n\n178.00\n\n+2.89%\n\n49B.F BeiGene, Ltd.\n\n13.50\n\n+3.85%\n\nUTH.F United Therapeutics Corporation\n\n293.20\n\n0.00%\n\nUNC.F UCB SA\n\n153.40\n\n-0.29%\n\nTF2.F Takara Bio Inc.\n\n6.05\n\n+3.42%\n\nDUL.F Alnylam Pharmaceuticals, Inc.\n\n237.90\n\n-0.08%\n\n0A3M.IL BioNTech SE\n\n83.53\n\n-2.40%\n\nSMS2.F PT Semen Indonesia (Persero) Tbk\n\n0.2160\n\n+0.93%\n\nH7T1.F HUTCHMED (China) Limited\n\n17.60\n\n+2.92%\n\nH7T2.F HUTCHMED (China) Limited\n\n3.2600\n\n-4.68%\n\n8AK.F Alkermes plc\n\n24.20\n\n+2.54%"
    }
}